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INTRODUCTION
Nebulizer solutions are widely used in the treatment of
asthma and chronic obstructive pulmonary disease. A number
of bronchial and nasal nebulizer preparations contain benza-
lkonium chloride (BAC) (1). Quaternary ammonium compo-
unds are used as antiseptics, disinfectants, detergents, and
preservatives, and of these BAC is the most frequently used.
BAC-induced contact allergy and bronchoconstriction have
been documented (2). We report a 23-yr-old woman present-
ing with anaphylactic shock following an intradermal skin
test with a nebulizer solution containing BAC. As far as we
could ascetain from available literatures, this is the first report-
ed case of anaphylaxis caused by benzalkonium in a nebulizer
solution.
CASE REPORT
A 23-yr-old woman who had complained of exacerbation
of cough and dyspnea after inhalation therapy with a nebu-
lizer solution was referred to our outpatient clinic. She had
been diagnosed with asthma 3 yr previously and treated with
a metered dose of a short-acting b2-agonist inhaler as needed.
She had no history of anaphylaxis, urticaria, or drug allergy.
On admission, a complete blood count, blood chemistry,
and serologic tests were normal. Chest radiographs revealed
no abnormalities. Her white cell count was 7,400/ L with
5% eosinophils and the serum total IgE was 256 IU/mL by
the EIA method. On spirometry, her forced vital capacity
and forced expiratory volume in 1 sec were 3,520 mL (90%
of the predicted value) and 2,700 mL (86% of the predicted
value), respectively. She underwent skin prick tests with a
panel of 10 common inhalant allergens and histamine (Aller-
gopharma Co., Hamburg, Germany) and serial dilution of
nebulizer solution containing BAC (Ventolin
�, GlaxoSmith-
Klein, U.K.). The skin prick test was positive only for house
dust mites species (Dermatophagoides farinae and D. pteronyssi-
nus). Subsequently, an intradermal skin test with a serial dilu-
tion of her nebulizer solution was performed. A positive reac-
tion was observed with 1:10 solution (wheal: 4×5 mm in
diameter, flare: 18×20 mm). About 10 min later, she pre-
sented with dizziness, palpitations, and dyspnea. Her blood
pressure was 70/30 mmHg, and her pulse was 120-140 per
minute. Electrocardiography showed no abnormal findings,
except for tachycardia. She was resuscitated with a subcuta-
neous injection of epinephrine (0.5 mg), an intravenous infu-
sion of saline, and oxygen. She recovered fully 3 hr later. After
obtaining oral informed consent, two healthy women with-
out atopy or allergies underwent intradermal skin tests with
the same nebulizer solution. Both control subjects were nega-
tive on tests. One month later, we conducted a bronchial pro-
vocation test with BAC following the method used by Asmus
et al. (1). The patient inhaled 3 mL of 0.9% NaCl solution
containing 600  g of BAC (benzalkonium chloride, Sigma,
St. Louis, U.S.A.). The solutions were prepared using asep-
tic techniques and stored at 2℃ in an Eppendorf tube. The
solutions were allowed to warm to room temperature imme-
diately before use. Each 3 mL dose was inhaled using nor-
mal tidal breathing through a DeVilbiss 646 nebulizer (DeVil-
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Anaphylaxis Caused by Benzalkonium in a Nebulizer Solution
Benzalkonium chloride (BAC) is commonly used as a bactericidal preservative in
nebulizer solutions, and can cause paradoxical bronchoconstriction following neb-
ulizing therapy in some asthmatics. We describe a case of anaphylactic shock in a
23-yr-old asthmatic woman following an intradermal skin test with a salbutamol solu-
tion containing BAC. Since she complained of cough and dyspnea after inhalation
therapy with a nebulizer solution, we conducted an intradermal skin test using the
same solution, which contained BAC. About 10 min later, the patient reported dizzi-
ness, palpitations, and dyspnea. On examination, tachycardia, tachypnea, and hypo-
tension were found. She was resuscitated with a subcutaneous injection of epine-
phrine and an infusion of saline. One month later, we conducted a bronchial provo-
cation test with BAC, and she showed a positive response.
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biss Co., Somerset, PA, U.S.A.). Spirometry was performed
at the beginning of the test and 15 min after inhalation of
each dose began. On BAC bronchial challenge, a drop in
FEV1 of 23% was noted after inhalation of 1,800  g BAC.
The patient refused skin test with BAC since she was aware
of her anaphylactic reaction.
DISCUSSION
This patient’s history and the results of the skin test and
BAC bronchial provocation test are consistent with anaphy-
laxis caused by a nebulizer solution containing BAC. Our case
showed a positive skin test to nebulizer solution and devel-
oped an anaphylactic reaction. This nebulizer solution con-
tained salbutamol and BAC. Although a positive bronchial
provocative response to BAC is not specific to diagnosis of
BAC-induced anaphylaxis, the immediate development of
symptoms and bronchoconstriction in response to BAC were
significant in this case. This result suggested BAC-induced
anaphylaxis.
BAC is one of the best known etiologic causes of contact
dermatitis and occupational asthma. It is found in cosmetics,
soaps, baby lotions, body lotions, and skin care products, as
well as in medical products, such as eye drops, ointments,
and solutions. Some bronchial nebulizer solutions contain
BAC as a bactericidal preservative, and it causes paradoxical
bronchoconstriction in some asthmatics when inhaled. The
mechanism of the allergic reaction caused by BAC and other
chemicals remains controversial (3). The previous reports on
BAC-induced asthma suggest that it induces anaphylaxis
via either IgE-mediated or non-IgE mediated mechanisms.
Our case showed a positive intradermal test, suggesting that
an IgE-mediated mechanism played a role in causing the reac-
tion. However, this does not exclude the possibility that BAC
also causes non-specific histamine release from mast cells via
surface activation. This is supported by previous reports of
dose-dependant histamine release from rat mast cells, and
antihistamine inhibition of the bronchoconstriction caused
by BAC (4, 5). In conclusion, our patient had an anaphylac-
tic reaction caused by the intradermal injection of benzalko-
nium chloride in her nebulizer solution. Although this is not
a common complication, such reactions may occur in patients
treated with nebulized solutions containing BAC.
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